Cardiovascular effects of GLP-1 receptor agonism-Reference-Cited by-同舟云学术

Cardiovascular effects of GLP-1 receptor agonism

Published:2022 Issue: Volume: Page:213-254
ISSN:1054-3589
Container-title:Advances in Pharmacology
language:
Short-container-title:

Author:

Winquist Raymond J.,Gribkoff Valentin K.

Publisher

Elsevier

Reference170 articles.

1. Hormones as regulators of pancreatic secretion in man;Adler;European Journal of Clinical Investigation,1990

2. The longer-term benefits and harms of glucagon-like Peptide-1 receptor agonists: A systematic review and meta-analysis;Alexander;Journal of General Internal Medicine,2021

3. Glucagon-like peptide-1 receptor action in the vasculature;Almutairi;Peptides,2019

4. Glucagon-like peptide 1 in health and disease;Andersen;Nature Reviews. Endocrinology,2018

5. GLP-1 receptor agonists and cardiovascular outcome trials: An update;Andrikou;Hellenic Journal of Cardiology,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression;2024-01-30

2. [Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases;Actas Dermo-Sifiliográficas;2024-01

3. Agonistas del receptor de GLP-1 para el tratamiento de la obesidad en pacientes con dermatosis inmunomediadas;Actas Dermo-Sifiliográficas;2024-01

4. Clinical pharmacology of antidiabetic drugs: What can be expected of their use?;La Presse Médicale;2023-03

5. Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy;Expert Opinion on Pharmacotherapy;2023-02-26